NCT03728777View on ClinicalTrials.gov

Resveratrol Supplementation in Patients With Mitochondrial Myopathies and Skeletal Muscle Fatty Acid Oxidation Disorders

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 9, 2018

Primary Completion Date

October 1, 2019

Study Completion Date

October 1, 2019

Conditions
Mitochondrial MyopathiesFatty Acid Oxidation Defects
Interventions
DIETARY_SUPPLEMENT

Resveratrol

Resveratrol supplementation 1000 mg /day or placebo

Trial Locations (1)

2100

Copenhagen Neuromuscular Center, Copenhagen

All Listed Sponsors
lead

Rigshospitalet, Denmark

OTHER

NCT03728777 - Resveratrol Supplementation in Patients With Mitochondrial Myopathies and Skeletal Muscle Fatty Acid Oxidation Disorders | Biotech Hunter | Biotech Hunter